{
  "patent_number": "US 12048738",
  "country": "US",
  "title": "Using mRNA to Teach the Body to Fight Prostate Cancer",
  "original_title": "Composition for treating prostate cancer (PCa)",
  "summary": "This patent describes an active composition, often a vaccine, that uses messenger RNA (mRNA) to instruct a mammal's cells to produce specific prostate cancer proteins, thereby training the immune system to attack prostate cancer cells.",
  "what_it_does": "The patent describes an \"active (immunostimulatory) composition\" designed to treat prostate cancer. This composition contains at least one RNA, specifically an mRNA, that carries instructions for making specific prostate cancer proteins, called antigens. For example, Claim 1 describes an isolated mRNA encoding Prostate-Specific Antigen (PSA). When this mRNA is introduced into a mammal, the body's cells use these instructions to produce the PSA protein. The immune system then recognizes this PSA protein as foreign and learns to attack cells that produce it, such as prostate cancer cells. Claim 16 further describes a composition with at least two different RNAs: one for PSA and another for a different prostate cancer antigen like PSMA, PSCA, or STEAP. This combination aims to create a stronger, more targeted immune response against the cancer.",
  "what_it_does_not_cover": [
    "Does not cover treatments for prostate cancer that do not involve an mRNA-based immunostimulatory composition.",
    "Does not cover mRNA compositions encoding only a single antigen other than PSA (e.g., an mRNA encoding only PSMA without PSA, as per Claim 16).",
    "Does not cover compositions using DNA or other types of RNA (like siRNA or tRNA) to stimulate an immune response.",
    "Does not cover mRNA compositions that encode antigens not selected from PSA, PSMA, PSCA, or STEAP for prostate cancer treatment.",
    "Does not cover methods of treatment that do not involve administering an effective amount of the specified mRNA or composition."
  ],
  "filed": "2019-08-22",
  "granted": "2024-07-30",
  "expires": "2039-08-22",
  "status": "active",
  "holder": "Curevac SE",
  "holder_url": "https://patentbrief.org/company/curevac-se",
  "inventors": [
    {
      "name": "Thomas Lander",
      "url": "https://patentbrief.org/inventor/thomas-lander"
    },
    {
      "name": "Ingmar Hoerr",
      "url": "https://patentbrief.org/inventor/ingmar-hoerr"
    },
    {
      "name": "Jochen Probst",
      "url": "https://patentbrief.org/inventor/jochen-probst"
    }
  ],
  "times_cited": 0,
  "tags": [
    "biotech",
    "pharmaceutical",
    "oncology",
    "gene_editing",
    "immunotherapy"
  ],
  "abstract": "The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate), The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.",
  "url": "https://patentbrief.org/patent/us/12048738/composition-for-treating-prostate-cancer-pca",
  "markdown_url": "https://patentbrief.org/patent/us/12048738/composition-for-treating-prostate-cancer-pca/md",
  "google_patents_url": "https://patents.google.com/patent/US12048738",
  "relatedPatents": [
    {
      "patentNumber": "20160166668",
      "countryCode": "US",
      "title": "How an mRNA Vaccine Targets Prostate Cancer with Six Antigens",
      "url": "https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer"
    },
    {
      "patentNumber": "20220096616",
      "countryCode": "US",
      "title": "Using Two Specific RNAs to Teach the Body to Fight Lung Cancer",
      "url": "https://patentbrief.org/patent/us/20220096616/composition-for-treating-lung-cancer-particularly-of-non-small-lung-cancers-nscl"
    },
    {
      "patentNumber": "20160168227",
      "countryCode": "US",
      "title": "How an mRNA Vaccine for Lung Cancer Teaches the Immune System to Fight",
      "url": "https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer"
    },
    {
      "patentNumber": "6824780",
      "countryCode": "US",
      "title": "How Genentech Created Antibodies to Target Prostate Cancer Cells",
      "url": "https://patentbrief.org/patent/us/6824780/avastin-dosing"
    },
    {
      "patentNumber": "11542303",
      "countryCode": "US",
      "title": "How a Specific Peptide Boosts the Immune System Against Cancer",
      "url": "https://patentbrief.org/patent/us/11542303/peptides-and-combination-thereof-for-use-in-the-immunotherapy-against-cancers"
    }
  ]
}